Syndax Pharmaceuticals
52
8
13
25
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
21.2%
11 terminated/withdrawn out of 52 trials
69.4%
-17.1% vs industry average
2%
1 trials in Phase 3/4
76%
19 of 25 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (52)
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Role: collaborator
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Role: lead
Menin-Inhibitor Targeted Maintenance in AML
Role: collaborator
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Role: collaborator
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Role: collaborator
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Role: collaborator
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Role: lead
Revumenib in Combination With 7+3 + Midostaurin in AML
Role: collaborator
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Role: lead
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Role: lead
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Role: collaborator
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Role: collaborator
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Role: lead
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Role: lead
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
Role: collaborator
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
Role: lead
Expanded Access Program for Revumenib
Role: lead
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Role: collaborator
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Role: collaborator
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Role: collaborator